Treatment_of_hypercalcemia_of_malignancy_with_intravenous_etidronate._A_controlled,_multicenter_study._The_Hypercalcemia_Study_Group__In_a_prospective,_randomized,_double-blind,_multicenter_study,_202_patients_with_cancer_from_19_medical_centers_were_treated_for_hypercalcemia_of_malignancy_with_daily_intravenous_infusions_of_etidronate_disodium_(136_patients)_or_saline_alone_(66_patients)_for_3_consecutive_days._Patients_also_received_up_to_3.25_L_of_saline_daily_during_the_treatment_period._Of_157_patients_for_whom_data_could_be_evaluated_for_efficacy,_63%_(72/114)_of_etidronate-treated_and_33%_(14/43)_of_saline-treated_patients_had_a_normalization_of_total_serum_calcium_levels._When_serum_calcium_levels_were_adjusted_for_albumin_(147_assessable_patients),_24%_of_the_etidronate-_and_7%_of_the_saline-treated_patients_responded_to_treatment._No_serious_side_effects_or_treatment-related_deaths_occurred._When_accompanied_by_adequate_hydration_and_diuresis,_intravenous_etidronate_was_safe_and_more_effective_than_hydration_and_diuresis_alone_in_controlling_hypercalcemia_of_malignancy.